Asset
VONAPRUMENT
Revenue
No revenue reported in loaded filings.
Clinical trials (4)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT06510816 | phase3 | active_not_recruiting | 2024-07-30 | 2027-07-31 | Annexon, Inc. | A Study Investigating the Efficacy and Safety of Intravitreal (IVT) Injections of Vonaprument (Formerly ANX007) in Participants With Dry Age-Related Macular Degeneration (AMD) With Geographic Atrophy (GA) |
| NCT04656561 | phase2 | completed | 2021-02-26 | 2023-03-28 | Annexon, Inc. | A Study Investigating the Efficacy and Safety of Intravitreal Injections of ANX007 in Patients With Geographic Atrophy |
| NCT07807969 | phase3 | not_yet_recruiting | 2026-09-30 | 2029-07-31 | Annexon, Inc. | An Open-label Extension Study of the Long-Term Safety of Vonaprument (ANX007) in Participants With Dry Age-Related Macular Degeneration (AMD) With Geographic Atrophy (GA) |
| NCT03488550 | phase1 | completed | 2018-03-23 | 2018-08-03 | Annexon, Inc. | Single-dose Study of ANX007 in Participants With Primary Open-angle Glaucoma |
FDA applications (0)
This company has no applications containing this asset.